Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $26.6 down -1.12% from its previous closing price of $26.9. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 2.25 million shares were traded. NAMS stock price reached its highest trading level at $27.35 during the session, while it also had its lowest trading level at $25.5545.
Ratios:
For a deeper understanding of NewAmsterdam Pharma Company NV’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27. On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.Citigroup initiated its Buy rating on June 17, 2025, with a $42 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 09 ’25 when Kooij Louise Frederika sold 150,000 shares for $25.83 per share. The transaction valued at 3,874,017 led to the insider holds 15,000 shares of the business.
Topper James N bought 1,260 shares of NAMS for $31,487 on Sep 08 ’25. The Director now owns 3,027,864 shares after completing the transaction at $24.99 per share. On Sep 09 ’25, another insider, Louise Kooij, who serves as the Affiliate of the company, bought 150,000 shares for $25.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 3029713408 and an Enterprise Value of 2257082880. For the stock, the TTM Price-to-Sale (P/S) ratio is 46.80 while its Price-to-Book (P/B) ratio in mrq is 3.84. Its current Enterprise Value per Revenue stands at 35.264 whereas that against EBITDA is -13.076.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.01, which has changed by 0.6666666 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 13.29%, while the 200-Day Moving Average is calculated to be 24.38%.
Shares Statistics:
For the past three months, NAMS has traded an average of 909.32K shares per day and 1219130 over the past ten days. A total of 112.51M shares are outstanding, with a floating share count of 73.12M. Insiders hold about 35.09% of the company’s shares, while institutions hold 61.58% stake in the company. Shares short for NAMS as of 1756425600 were 7497579 with a Short Ratio of 8.25, compared to 1753920000 on 7179587. Therefore, it implies a Short% of Shares Outstanding of 7497579 and a Short% of Float of 7.9399999999999995.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of NewAmsterdam Pharma Company NV (NAMS).The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.2. EPS for the following year is -$1.72, with 10.0 analysts recommending between -$1.12 and -$2.52.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.21M, while the lowest revenue estimate was $18.99M, resulting in an average revenue estimate of $27.2M. In the same quarter a year ago, actual revenue was $43.39M
